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ABSTRACT 
  AITKEN,CHELSEA  Biological activity of a set of new copper(II) 
complexes: toward understanding structure-reactivity correlations  
 
 
  ADVISOR:  Professor Laurie A. Tyler 
Cisplatin, carboplatin and oxaliplatin are all platinum-containing complexes that 
have been approved for use as chemotherapy drugs. The success of these complexes as 
well as their downfalls have sparked interest into alternative transition metal based 
compounds as potential chemotherapeutic agents. The use of platinum based complexes 
in cancer treatment has faced complications including cytotoxicity and drug resistance. 
The use of copper(II) as an alternative metal center is of specific interest because of  
bioavailability and elevated concentrations of this metal ion within tumor cells. Three 
copper complexes that utilize a nitrogen based ligand system, two of which contain a 
thiazole moiety have been synthesized and characterized. The biological activity and 
potential cytotoxicity of these complexes was measured on the basis of nuclease activity, 
DNA binding, and interaction with BSA. These characteristics were determined by 
quantitative analysis of studies using ethidium bromide, gel electrophoresis, and UV-Vis 
spectroscopy. It has been shown that all of these complexes exhibit concentration 
dependent nuclease activity utilizing a mechanism dependent on reactive oxygen species. 
Here, comparisons between the activity of these newly synthesized compounds and those 
previously studied are presented to aid in developing a correlation between ligand 
structure and complex activity.  
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 1 
1. Introduction 
 
The American Cancer Society estimated that in the U.S. 1,638,910 new cases of 
cancer were diagnosed in 2012 alone and 577,190 cancer related deaths occurred.1 These 
numbers demonstrate the prevalence of cancer and highlight the great impact it has on 
our lives. Most of our lives have been touched by cancer in some way, whether as the 
patient, a family member, or a friend. Research in this field is ongoing and of extreme 
importance.   
 
In humans, all the cells within a tumor are believed to originate from a single cell 
that was converted from a normal cell to a cancerous cell. This type of cancer origination 
is named monoclonal, the other possibility (polyclonal origination) has not been observed 
in humans.2 The next question then becomes how does a cell convert from a normal cell 
to a cancerous one. Cancer occurs once multiple mutations have been sustained and 
propagated. Often these mutations are specific to genes responsible for regulating cell 
cycle control, allowing the cancerous cells to proceed through the cell cycle and produce 
progeny despite sustained mutations.2 Typically a single mutation, particularly in an 
essential gene, will promote a cell to undergo programmed cell death preventing the 
spread of that mutation to subsequent generations of cells. However, some mutations are 
not repaired in time and in many cases with pre-cancerous mutations the mutated gene 
actually allows the daughter cells to be more susceptible to sustaining subsequent 
mutations because the initially mutated gene was involved in a pathway responsible for 
cell division control or DNA damage monitoring.2,3 Cancer is not really a single disease, 
but rather many diseases with one unifying factor, the ability of cells to proliferate 
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without regulation.3 A tumor is a mass of these mutated cells that are dividing without 
regulation and the tumor is considered malignant once the cancerous cells begin to invade 
tissues outside of their native region in the body.  Cancers can be divided into four 
predominant types: carcinomas, sarcomas, leukemia, and lymphoma.3  
 
1.1 Inducing programmed cell death in cancerous cells 
  
 Apoptosis is a form of highly controlled internally initiated cell death. Various 
factors, intracellular and extracellular, can be responsible for triggering this response in 
cells.  This type of cell death is advantageous because the cell shrinks and then breaks 
into membrane enclosed fragments, which can later be digested without any harm to 
surrounding cells.4,5 There are three circumstances under which apoptosis typically occur. 
The first involves apoptosis initiated by environmental factors, such as limited physical 
space or cellular resources this is termed utilitarian cell suicide, because a perfectly 
healthy cell undergoes cell death for the overall benefit of the surrounding cellular 
population.4 This is specifically useful during development. Apoptosis can also be 
triggered in cells once they have reached or surpassed their cellular life expectancy; this 
is called senescent cell suicide.4 Finally, the situation that triggers apoptosis that is most 
relevant to our discussion of cancer and cancer treatments, involves the initiation of 
apoptosis due to cellular damage. Damage to DNA, cellular membranes, or other vital 
cellular components induces the cell to initiate programmed cell death rather than risk 
incorrectly repairing the damage and propagating it to subsequent generations.4 
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There is a strong correlation between genes involved in the apoptotic pathway and 
cancer. Tumor suppressor genes are typically involved in controlling proliferation and do 
so by acting as signals in control pathways including apoptosis, cell cycle, and DNA 
repair. Genes are considered tumor suppressors not only because they are essential in 
these types of pathways, but also because their absence has been shown to promote 
cancer.5 p53 is one of the quintessential tumor suppressor genes and a mutation in this 
gene is found in the majority of all human tumors.6 In healthy cells, p53 accumulates in 
response to cellular stress, such as extensive DNA damage, and then functions as an 
activator in the apoptotic pathway. Mutations in the genes responsible for encoding p53 
result in cells that evade apoptosis and survive despite damage that should cause them to 
initiate programmed cell death.5 This type of mutation is advantageous for cancerous 
cells because in order to proliferate without control in non-native environments they need 
to evade checkpoints that function to kill cells with these characteristics. Several other 
oncogenes have been discovered that are a part of the apoptotic pathway. The protein 
Bcl-2 is known to act as an anti-apoptosis signal and is often over expressed in cancerous 
cells. Some oncogenes are actually responsible for promoting apoptosis, one example is 
Myc which functions as both a promoter of cell proliferation and a promoter of 
apoptosis.5 This dual functionality is a useful control in healthy cells because it ensures 
that cells need both an activating signal from Myc and an anti-apoptotic signal in order to 
continue proliferating. However, in the presence of consistent anti-apoptosis signals such 
as when bcl-2 is overexpressed, the proliferating activity of Myc continues to be active 
allowing the cells to continuously divide without initiating cell death.5  
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Even though apoptotic pathways are often malfunctioning in cancerous cells, the 
induction of apoptosis is an important aim of many cancer treatments. The complex 
relationship between tumor development and alterations of the cells’ ability to initiate 
programmed cell death makes apoptosis an interesting target for cancer treatments; the 
goal is to trigger apoptosis more readily in the mutated cells than in the patients’ healthy 
cells.7 Tumors with mutations in genes such as p53 have increased risk of being resistant 
to these treatments because of their inactivated apoptotic pathways. On the other hand, 
tumors that have activated oncogenes such as Myc are often more receptive to treatment 
because apoptosis can be triggered more easily.5 Chemotherapeutic drugs that induce 
apoptosis in tumor cells also promote apoptosis in healthy cells, which is one of the 
causes of cytotoxicity and other negative side effects experienced with chemotherapy.6 
Some current studies are focusing on designing chemotherapy drugs that target specific 
effector molecules within the apoptosis pathway, however historically many successful 
chemotherapy drugs have the simple aim of damaging DNA in order to promote 
apoptosis. It is important to note that inflicting DNA damage on cancerous cells also has 
the ability to promote other types of cell death such necrosis, mitotic catastrophe, 
autophagy, and early senescence. Historically a focus had been placed on apoptosis, 
however the ability to selectively induce cell death in any capacity is a promising 
characteristic of any potential anti-cancer agent.8  
 
1.2 Cancer treatments currently available and how they function 
 
 For the most part cancer treatments fall into three main categories: surgery, 
radiation, and chemotherapy. Many cancer treatment plans involve the use of two or 
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more of these treatments administered either simultaneously or in succession.9 Surgery is 
typically used for cancers that are isolated and have yet to metastasize. In this case the 
goal of surgery is to remove the entirety of the tumor and sometimes radiation or 
chemotherapy is administered post operatively to kill off any cancerous cells the surgery 
may have missed. Alternatively, surgery can be used to reduce the size of a large tumor 
that cannot be removed entirely before starting radiation or chemotherapy to increase the 
chances of success with one of these treatments.9 Radiation therapy uses X-rays to 
eliminate tumors. The concept behind this treatment is that the X-rays will induce DNA 
damage within the exposed cells and the actively dividing mutated cancer cells will be 
less able to repair this damage than healthy cells, promoting an increased rate of cell 
death in the cancerous cells.  Since this treatment relies on damaging DNA there is a 
small risk that a patient will develop a different cancer as a result of receiving radiation 
therapy.9  
 
The final category of available treatment options is chemotherapy, which actually 
encompasses a wide range of cytotoxic drugs that work by inhibiting cellular growth or 
promoting cell death. One of the benefits of this type of treatment is the fact that it’s 
systemic so it can be used for cancers that are not tumorous and those that have 
metastasized before they have formed masses large enough to detect.9 Since the aim of 
these drugs is to disrupt cell proliferation the target of their activity is often DNA, 
because the cells need functional DNA in order to replicate and proceed through the cell 
cycle. Some of these agents work by altering the structure of DNA bases thus limiting 
reactivity of enzymes involved in replication, some work by creating crosslinks between 
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the bases so that they cannot be separated and others are successful by causing breaks on 
one or both strands in the double helix.9    
 
1.3 Metal complexes as chemotherapy agents 
 
 Platinum-containing complexes such as cisplatin, carboplatin and oxaliplatin are 
all examples of metal complexes that have been approved for use as chemotherapy 
drugs.10 The structure of each of these complexes is shown in Figure 1.  
 
   
Figure 1. Structures of cisplatin, carboplatin, and oxaliplatin. (Figures taken from Clinical Status 
of Cisplatin, Carboplatin, and Other Platinum-Based Antitumor Drugs13) 
 
 
  Cisplatin is known to work by covalently boding to DNA and creating cross-
linkages, which causes the DNA to kink and become inaccessible to DNA replication 
machinery.10,11  Once cisplatin crosses the membrane and enters a cell it is surrounded by 
an aqueous environment with a lower chloride concentration; as a result one of the 
chloride groups is typically replaced with a water molecule. After water has bound to 
cisplatin, the complex becomes a positively charged species that is highly reactive with 
DNA’s negatively charged backbone.10 Cisplatin is known to preferentially bind with 
deoxyguanosines and create interstrand, intrastrand, and DNA-protein cross-linkages. 
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Interstrand cross-linkages result from one cisplatin binding to two bases on opposite 
strands of the double helix, whereas intrastrand cross-linkages result from binding to two 
bases on the same strand. These alterations of the DNA, shown in Figure 2, are thought to 
be the main source of cisplatin’s cytotoxicity because the damage often induces 
apoptosis.10,11 Radio-labeling has shown that the majority of linkages formed are 
intrastrand and it is generally accepted that these linkages contribute most to cisplatin’s 
overall cytotocity.12,13 Due to the damage interrupting DNA replication, the cytotoxicity 
is specific to rapidly dividing cells, such as cancerous ones. Cisplatin has been used to 
effectively treat testicular, ovarian, lung, head, neck, and bladder cancers.14 Although the 
success of cisplatin has made great improvements in cancer treatment and survival, it is 
also linked to a number of negative side effects including nephrotoxicity and 
neurotoxicity. As a result, the search for cisplatin analogs that are less toxic to healthy 
cells and ultimately less damaging to the patient continues to be at the forefront of 
research efforts.  
 
Figure 2. Structure of interstrand and intrastrand adducts on DNA caused by cisplatin. 
(Figures taken from: The Mechanism of Action of Cisplatin: From Adducts to Apoptosis 11) 
  
 
Carboplatin was designed as a cisplatin analog. The design behind the synthesis 
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of this drug was replacing the labile chloride groups in cisplatin with more stable ligands 
in an effort to lower the overall toxicity of the compound, in order to minimize negative 
effects on healthy cells. As hoped, carboplatin proved less toxic than cisplatin and has 
similar effectiveness as an anti-cancer drug by causing similar adducts on DNA.14  
 
Oxaliplatin is a cisplatin analog that not only has more stable ligands in place of 
chloride groups, but also has diaminocyclohexane in place of the two amine groups. 
Similarly to cisplatin, this anti-cancer agent is known to function by inducing three 
different types of crosslinks on DNA: intrastrand, interstrand, and DNA-protein. As with 
the other complexes these crosslinks serve to arrest the cell cycle and eventually promote 
apoptosis. Although the main mode of inflicting DNA damage seems to be the same, the 
structural differences have allowed oxaliplatin to be useful in the treatment of digestive 
system cancers, which are untreatable with cisplatin and carboplatin.15  
 
Although these three platinum containing compounds have been successful in 
treating certain types of tumors, their usage faces certain restrictions. These obstacles 
include cells building resistance to platinum-based anti-cancer drugs, the toxicity of the 
metal having negative impacts on the rest of the body, and an insufficient amount of 
uptake by the cell. Some studies have used the properties of copper in order to aid the 
transport of platinum-based complexes, because specific channels exist to allow its 
transport into the cell.16 
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1.4 Copper based compounds as potential chemotherapeutic agents  
  
Copper is naturally occurring in the body and its role in redox chemistry makes it 
an essential element needed for many basic biochemical reactions. Ideally the 
bioavailability of copper will result in lower toxicity levels of copper containing anti-
cancer complexes compared to other non-essential transition metals such as platinum.17 
Additionally, it has been found that copper concentrations are elevated in tumors and its 
presence is thought to be essential for angiogenesis.18 Overall, copper complexes show 
great potential as anti-cancer agents because the metal involved may be selectively 
shuttled to cancerous masses within the body.  
 
The reactivity of copper complexes is assessed by DNA cleavage, protein binding, 
and DNA binding. Previously, in the Tyler research group utilized ligand frames 
containing substituted thiazole groups, specifically where R= 8-hydroxyquinoline, 2-
pyridine, and 2-quinoline.  The synthetic scheme for these ligands is shown in Figure 3.  
 
 
Figure 3. Reaction for thiazole ligand compounds, where R represents the groups being 
altered. 
 
 
Project Description 
 
The goal of my project will be to synthesize new Cu(II) based ligand complexes by altering the 
thiazole based ligand system. The general reaction for the synthesis of the thiazole ligand is shown in 
Figure 1.  
Figure 1. Reaction for thiazole ligand compounds, where R represents the groups being altered. 
 
 Previously, in the Tyler research group, R = 8-hydroxyquinoline has been synthesized and the 
corresponding Cu(II) complexes isolated and characterized. This complex has been assessed for 
biological activity including DNA binding and cleavage studies.  
This summer, I will focus on synthesizing a new thiazole based ligands and their copper 
complexes in order to provide a set of complexes for comparison.  The R groups in Figure 2 will be 
used and the corresponding aldehydes are available for purchase from Sigma-Aldrich Chemical 
Company. 
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Several corresponding Cu(II) complexes with these ligands have been isolated 
and characterized. The complexes shown in Figure 4 were tested for biological activity 
by lab members Han Lin and David Foreman.19,20 These complexes were assessed for 
biological activity using the aforementioned criteria DNA binding, protein binding, and 
DNA cleavage. 
 
          
 
 
 
 
 
 Studies of the compounds shown in Figure 4 demonstrated that the structural 
differences between them influenced their efficiency for DNA cleavage and the strength 
of DNA binding. DNA cleavage studies indicated that compound 2 had the greatest DNA 
cleavage efficiency while compound 4 had the least efficiency. DNA binding studies 
using EtBr indicated that compound 1 intercalates DNA with the greatest strength and 
Figure 4. Crystal structures of Cu(8OHQ(oBt))Cl2 (1)  Cu(8OQ(oBt))Cl (MeOH) (2) 
Cu(Q(oBt))(H2O)(NO3)2 (3)  and [Cu(Py(oBt))2H2O]2+(BF4)2 (4) 19.20 
1 2 
3 4 
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compound 4 intercalates with the least strength. Protein binding studies did not provide 
comparative results because binding constants were not determined.19  
 
This project is an extension of the aforementioned work. I have synthesized new 
thiazole based ligands and the corresponding copper complexes. These complexes have 
been tested for biological activity in the same manner as those previously studied and 
reactivity and binding strength comparisons have been made between all the complexes 
tested up to this point.  
 
2. Experimental 
 
2.1 Material 
 
All starting materials were purchased from Sigma Aldrich and were used in their 
original condition without further purification. Anhydrous solvents were also purchased 
from Sigma Aldrich and left untreated.  
 
2.2 Instruments 
 
H1 NMR spectra were collected using a 400 MHz Brüker Avance NMR 
spectrometer. Infrared spectra were collected using a Nicolet Avatar 330 FT-IR with 
smart orbit solid-state attachment. Absorbance spectra were obtained using an Agilent 
8453 spectrophotometer. Fluorescence spectra were collected using an 810 
Photomultiplier Detection System spectrophotometer. A Bio Rad PowerPac 300 was used 
for DNA separation via agarose gel electrophoresis. Gel images were recording using a 
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Syngene G:Box and analysis of band density was performed using the 
Syngene:GeneTools program.  
 
2.3 Preparation of Ligands  
2.3.1 PyOMe(oBt)   
 
The ligand, PyOMe(oBt), was synthesized in the following way: 346 µL (2.88 
mmol) of 6-methoxy-2-pyridine carboxaldehyde and 308 µL (2.88 mmol) of 2-
aminothiophenol were added to ~20 mL of ethanol (EtOH).  The reaction was refluxed 
for 1 h. After refluxing, the solution was left to heat open to air for an additional hour, as 
a result the volume was reduced to ~5 mL via evaporation and a white precipitate formed. 
The product was collected via vacuum filtration, washed with EtOH, and then dried 
under vacuum for 1 h. Yield: 755 mg (47%). 1H NMR (CDCl3, 400 MHz, 25º C, δ from 
TMS): 8.08 (d, 1H, J = 8.16 Hz), 7.95 (m, 2H), 7.728 (m, 1H), 7.50 (m, 1H), 7.40 (m, 
1H), 6.86 (d, 1H, J = 8.24 Hz), 4.07 (s, 3H). Selected IR bands: (cm-1) 1574 (νN=C), 1421 
(s), 724 (s), 801 (m). 
 
2.3.2 PyOMe(en) 
 
The ligand, PyOMe(en), was synthesized in the following way: 720 µL (5.98 
mmol) of 6-methoxy-2-pyridine carboxaldehyde and 200 µL (2.99 mmol) of ethylene 
diamine (en) were added to ~30 mL of EtOH.  The reaction was refluxed for 1 h resulting 
in a color change to bright yellow. The solution volume was then reduced to ~10 mL via 
rotoevaporation resulting in the formation of a white solid. The product was collected via 
vacuum filtration, rinsed with hexanes, and then dried under vacuum for 1 h. Yield: 311.4 
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mg (49%). 1H NMR (CDCl3, 400 MHz, 25º C, δ from TMS): 8.30 (s, 1H), 7.58 (m, 2H), 
6.76 (d, 1H, J = 7.72 Hz), 4.02 (s, 2H), 3.95 (s, 3H). Selected IR bands: (cm-1) 1587 
(νN=C), 1019(m), 730 (s). 
 
2.4 Synthesis of Complexes  
 
2.4.1 Cu(PyOMe(oBt))Cl2 (1) 
 
 First, the ligand PyOMe(oBt) (260.9 mg, 1.10 mmol) was dissolved in ~10 mL 
MeOH. Separately, copper chloride (185.8 mg, 1.10 mmol) was dissolved in ~5 mL 
MeOH. Next, the metal solution was added dropwise to the ligand solution. The solution 
turned a deep brown color upon addition of the metal salt.  The solution was stirred for 24 
h and then gravity filtered.  Upon slow diffusion of diethyl ether (Et2O) into this brown 
solution resulted in the formation of, orange-brown, block like crystals. Yield: 166 mg 
(17.1%). Selected IR bands: (cm-1) 1573 (νN=C), 1429 (s), 732 (s), 806 (m). Electronic 
absorption spectrum in MeOH: λmax (nm) (ε, M-1 cm-1) 322 (40213).  
 
2.4.2 [Cu(PyOMe(oBt)2(NO3)]NO3 (2) 
 
Ligand, PyOMe(oBt) (192.7 mg, 0.82 mmol) and copper nitrate (95.2 mg, 
0.41mmol) were separately dissolved in ~10 mL of methanol (MeOH).  Next, the metal 
was added dropwise to ligand. Upon addition of the metal the solution turned brown-
yellow and a lime green solid formed almost immediately. The solution was allowed to 
stir for 6 h and then gravity filtrated. Upon slow diffusion of acetonitrile (ACN), the 
brown solution turned a bright green color similar to the initial solid collected. The 
solution was then left to slowly evaporate. After several days large green block like 
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crystals had formed. Yield: 62.8 mg (27.5%). Selected IR bands: (cm-1) 1427 (s), 728 (s), 
808 (m). Electronic absorption spectrum in MeOH: λmax (nm) (ε, M-1 cm-1) 322 (34194). 
 
2.4.3 [Cu2(PyOMe(en))(PyOMe(enH2)2](NO3)4 (3)    
 
First, the ligand PyOMe(en) (217.8 mg, 0.73mmol) was dissolved in ~10 mL 
anhydrous MeOH then copper nitrate (169.8 mg, 0.73mmol) was separately dissolved in 
~10 mL anhydrous MeOH.  Next, the metal solution was added dropwise to the ligand 
solution. The colorless solution turned a deep aqua color upon addition of the metal 
solution.  The solution was stirred for 24 h and then gravity filtered.  Upon slow diffusion 
of Et2O into the solution, deep blue crystals formed. Yield: 45.5 mg (19.1%). Selected IR 
bands: (cm-1) 1592 (νN=C), 999(m), 732 (s).  
 
2.5 Solution Preparations 
 
2.5.1 TAE Buffer (1X) 
 
50X TAE Buffer was prepared at outlined in Fox Research Lab Protocols.21 20 
mL of the 50X buffer was then diluted to a final volume of 2 L with deionized water.  
 
2.5.2 Tris-HCl Buffer (5 mM Tris, pH 7.2) 50 mM NaCl 
 
First, Tris (151.4 mg) was dissolved in ~ 200 mL of deionized water and then 
NaCl (730 mg) was also added into the solution. The desired pH was reached by titrating 
with 0.1M HCl and/or 0.1M KOH while monitoring the solution using a pH electrode. 
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Once a pH reading of 7.2 was reached the solution was diluted to a final volume of 250 
mL with deionized water in a graduated cylinder. 
 
2.5.3 Stock Complex Solutions (1000 µM) 
 
Complex 1 (7.5 mg) and 2 (7.1 mg) were weighed out using an analytical balance 
and then separately diluted to a final volume of 10 mL with dimethylformamide (DMF) 
in a volumetric flask.  The solution was shaken until complex was completely dissolved 
and then stored at room temperature and used within 24 h of preparation. 
 
2.5.4 Ascorbic Acid Stock Solution (2000 µM and 1000 µM) 
 
The stock solution was prepared by first obtaining 3.52 mg and 1.76 mg of 
ascorbic acid respectively diluting to a final volume of 10 mL with 5 mM Tris, 50 mM 
NaCl pH 7.2 Buffer (prepared as outlined above) in a volumetric flask. Solid was 
dissolved via shaking and then solutions were stored at 12°C for future use.  
 
2.5.5 Plasmid DNA Preparation  
 
The plasmid DNA preparation was performed by first transforming E.coli cells 
via electroporation using the procedure outlined in Fox Research Lab Protocols (1-9).21 
Once the cells were transformed the procedure for plasmid mini-prep was followed (Fox 
Research Lab Protocols (1-12)).21  Once a purified sample of plasmid DNA was obtained 
the concentration was determined using the nanodrop by following the procedure 
outlined in Fox Research Lab Protocols (2-1).21 
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2.5.6 Calf Thymus DNA (CT-DNA) Stock Solution 
 
CT-DNA stock solution was prepared using the procedures outlined in Foreman 
et al.20 
 
2.5.7 Bovine Serum Albumin (BSA) Stock Solution (50 µM) 
 
BSA stock solution was prepared using the procedures outlined in Foreman et 
al.20 
 
2.6 Biological Studies 
 
2.6.1 DNA Cleavage and Mechanistic Studies  
 
DNA cleavage studies were performed by preparing ten different solutions of 
varying complex concentration that were composed of 5 mM Tris, 50 mM NaCl, pH 7.2 
buffer, ascorbic acid at a concentration twice that of the given complex concentration, 
and plasmid DNA of a constant concentration of 0.01 µg/µL. Buffer was added to ensure 
each sample had a final volume of 30 µL and were prepared in accordance with the 
amounts shown in Table 1. Plasmid DNA was always added last and the final solution 
was mixed by pipetting up and down.  
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Table 1. Sample preparation for DNA cleavage studies using 1000 µM stock complex 
solution and 1000 µM stock ascorbic acid solution.  
 
Lane # 
Complex 
Concentration 
(µM) 
Compound 
volume (µL) 
DNA 
volume 
(µL) 
[AH2] 
(µM) 
AH2 
volume 
(µL) 
Buffer 
volume 
(µL) 
1     0     0     1     0     0     29     
2     100     3     1     200     6     20     
3     125     3.75 1     250     7.5  17.75  
4     150     4.5 1     300     9     15.5 
5     175     5.25 1     350     10.5  13.25 
6     200     6     1     400     12     11     
7     225     6.75 1     450     13.5 8.75 
8     250     7.5 1     500     15     6.5 
9     275     8.25 1     550     16.5 4.25 
10     300     9     1     600     18     2     
 
 
The DNA cleavage mechanistic studies were performed in a similar experimental 
set up was used.  Ten solutions of varying complex concentration with the same 
composition shown in Table 1, except these experiments included the addition of either 
L-histidine or DMSO.  The volumes of each solution present in each of these samples are 
outlined in Table 2 and Table 3.  
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Table 2. Sample preparation for L-histidine mechanistic studies using 1000 µM stock 
complex solution and 2000 µM stock ascorbic acid solution and 50 mM stock of L-
histidine. 
 
Lane 
# 
Compound 
(µM) 
Compound 
(µL) 
DNA 
(µg/µL) 
DNA  
(µL) 
[AH2] 
(µM) 
AH2 
(µL) 
L-
Histidine 
(µM) 
L-
Histidine 
(µL) 
Buffer 
(µL) 
1 0 0 0.01 1 0 0 2000 1.2 27.8 
2 100 3 0.01 1 200 3 2000 1.2 21.8 
3 125 3.75 0.01 1 250 3.75 2000 1.2 20.3 
4 150 4.5 0.01 1 300 4.5 2000 1.2 18.8 
5 175 5.25 0.01 1 350 5.25 2000 1.2 17.3 
6 200 6 0.01 1 400 6 2000 1.2 15.8 
7 225 6.75 0.01 1 450 6.75 2000 1.2 14.3 
8 250 7.5 0.01 1 500 7.5 2000 1.2 12.8 
9 275 8.25 0.01 1 550 8.25 2000 1.2 11.3 
10 300 9 0.01 1 600 9 2000 1.2 9.8 
 
 
 
Table 3. Sample preparation for DMSO mechanistic studies using 1000 µM stock 
complex solution and 2000 µM stock ascorbic acid solution and pure DMSO. 
 
Lane # 
Compound 
(µM) 
Compound 
(µL) 
DNA 
(µg/µL) 
DNA 
volume 
(µL) 
[AH2] 
(µM) 
AH2 
(µL) 
DMSO 
(µL) 
Buffer 
(µL) 
1 0 0 0.01 1 0 0 3 26 
2 100 3 0.01 1 200 3 3 20 
3 125 3.75 0.01 1 250 3.75 3 18.5 
4 150 4.5 0.01 1 300 4.5 3 17 
5 175 5.25 0.01 1 350 5.25 3 15.5 
6 200 6 0.01 1 400 6 3 14 
7 225 6.75 0.01 1 450 6.75 3 12.5 
8 250 7.5 0.01 1 500 7.5 3 11 
9 275 8.25 0.01 1 550 8.25 3 9.5 
10 300 9 0.01 1 600 9 3 8 
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Once the solutions were prepared the procedure for the DNA cleavage studies and 
the mechanistic studies was identical.  The solutions were left to incubate at 37°C for 2 h. 
After incubation the samples were centrifuged at maximum speed in the microfuge for 5 
min and then 10 µL from each sample was transferred to a separate tube. Next, 2 µL of 
6X loading dye was mixed into the 10 µL samples and then the total volume of 12 µL 
was loaded into a 1% agarose gel in 1X TAE running buffer. The gel was prepared using 
the procedure outlined in Fox Research Lab Protocols (3-1).21 The gel was run at 80 V 
for 1 h 15 min and then stained in 0.5 µg/mL EtBr for 30 min. After staining, the gel was 
de-stained in deionized water for 10 min.   
 
2.6.2 DNA Binding Ethidium Bromide (EtBr) Fluorescence Studies 
 
DNA Binding studies were performed using the procedures outlined in Foreman 
et al and Lin et al.19,20  
 
2.6.3 Bovine Serum Albumin (BSA) Binding Fluorescence Studies 
 
BSA binding studies were performed using the procedures outlined in Foreman et 
al and Lin et al.19,20  
 
3. Results and Discussion 
 
3.1 Synthesis and Characterization of Ligands 
 
The ligands PyOMe(oBt) and PyOMe(en) were synthesized by reacting 6-
methoxy-2-pyridine carboxaldehyde with 2-aminothiophenol and ethylene diamine, 
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respectively. The reactions were carried out in methanol and the structures of these 
ligands were confirmed via IR and 1H-NMR spectroscopies. The PyOMe(oBt) ligand was 
formed via the condensation reaction shown in Scheme 1. The initial product formed was 
typically the thiazoline intermediate shown (Scheme 1, line 2, left), however upon 
oxidation in air only the final thiazole product was obtained. The two different products 
can be distinguished using 1H-NMR spectroscopy based upon the disappearance of the 
peaks associated with –NH and –CH shifts.22 Appendix 1 depicts the 1H-NMR spectrum 
of the final thiazole product, PyOMe(oBt), which lacks both of these characteristic 
thiazoline peaks and contains peaks and integration expected for the thiazole product.   
The PyOMe(en) ligand was formed via the reaction shown in Scheme 2, which also 
results in the formation of H2O as a byproduct. The condensation reaction could possibly 
lead to both the mono- and disubstituted amine. 1H-NMR spectroscopy was used to 
confirm that the product isolated was the disubstituted ligand containing two imine 
groups based on the absence of a peak corresponding to NH2. The 1H-NMR spectrum of 
the final product is shown in Appendix 2.  
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Scheme 1. Reaction scheme for synthesis of PyOMe(oBt) ligand. Top:  condensation of 
2-aminothiophenol with 6-methoxy-2-pyridinecarboxaldehyde to form the corresponding 
thiazoline.  Bottom:  air oxidation of the thiazoline to afford the thiazole containing 
ligand. 
 
 
 
Scheme 2. Reaction scheme for synthesis of PyOMe(en) ligand. Condensation of 
ethylene diamine with 6-methoxy-2-pyridinecarboxaldehyde.  
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3.2 Synthesis and Characterization of Cu(II) Complexes  
 
The corresponding copper(II) complexes were obtained for both ligands. 
Interestingly, two complexes were isolated for the PyOMe(oBt) ligand as a result of 
reacting it with both CuCl2 and Cu(NO3)2, respectively. A single complex was isolated 
for the PyOMe(en) ligand. This complex was a product of the ligand’s reaction with 
Cu(NO3)2.  Structures of these complexes were determined via X-ray crystallography. 
Thermal ellipsoid plots showing the crystal structures of these complexes are shown in 
Figure 5.  
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Figure 5. Thermal ellipsoid plots (50% probability level) of complexes 1 (top left), 2 (top 
right), and 3 (bottom). For complexes 2 and 3, H atoms and NO3- counter ions have been 
omitted for clarity.  
 
 
 Synthesis of complex 1 resulted in the formation of orange-brown crystals with 
block like morphology. Ligation of the ligand was confirmed by analysis of the IR 
spectrum of the complex compared to the IR spectrum of the free ligand (Appendix 3). 
Upon coordination, the spectrum revealed several resonances that shifted to lower energy 
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indicative of coordination (Appendix 4). X-ray analysis showed that complex 1 is a dimer 
with two copper centers ligated to one ligand (N,N). The coordination sphere around each 
copper is completed by two chloride ions, one terminal and one bridging. The bond 
length between Cu-NPy is 2.020 Å, whereas the bond length between Cu-Nthiazole is 2.271 
Å. The bond angle between these three atoms is 77.7°. The bond angle between NPy -Cu-
Cl was 91.1° and the angle between Nthiazole-Cu-Cl was 104.4° giving rise to distorted 
trigonal bipyrimidal geometry around each metal center. 
  
Synthesis of complex 2 yielded large green block like crystals. The IR spectrum 
of these crystals is shown in Appendix 5. Upon coordination of the ligand, several IR 
resonances shift to lower energy, indicative of coordination. The ellipsoid plot obtained 
via X-ray analysis showed complex 2 is a monomer with two ligands  bound to each 
Cu(II) center  and one O-bound nitrate with an overall +1 charge.  The N4O coordination 
sphere around the metal center gives rise to a distorted trigonal bipyriamidal geometry.  
 
Synthesis of complex 3 yielded large deep blue sea urchin like crystals. Appendix 
6 shows an IR spectrum of the starting ligand and Appendix 7 shows an IR spectrum of 
complex 3 crystals for comparison. Similar to the complexes previously mentioned, the 
IR spectrum of complex 3 revealed several resonances that shifted to lower energy upon 
coordination to the metal center. X-ray analysis yielded very interesting results because 
the structure of complex 3 was shown to contain two metal centers. Each copper center 
was ligated to one partially hydrolyzed ligand (PyOMe(enH2)) ligand and one 
unhydrolyzed ligand (PyOMe(en)) that bridged between the two metals. The geometry of 
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the N5 coordination sphere around each metal center is best described as distorted square 
pyriamidal.  The bond lengths between Cu-NPy were 2.023 and 1.962 Å with an angle of 
82.5°. The bond lengths between Cu-Nen were 2.017, 2.097, and 2.246 Å with angles of 
169.1° and 77.3°. The bond angle between Nen-Cu-NPyOMe was 102.0°. 
 
The observed structural differences between complexes 1 and 2 demonstrate the 
impact that the starting metal has on the overall structure of the complex.  However, for 
complex 3 there were inconsistencies between the molecular weight indicated by the X-
ray crystal structure and the elemental analysis data. This made it unclear whether the 
complex was undergoing the same extent of hydrolysis every time the reaction was 
carried out. Experimentation with this complex is still ongoing, however, until the 
molecular weight and crystal structure data match the elemental analysis for the bulk, 
complex 3 cannot be tested for biological activity.  
 
3.2 DNA Cleavage Studies  
 
DNA is a common target of chemotherapy drugs because of its key role in cellular 
proliferation. Cells require DNA that is both intact and accessible to replication 
machinery in order to divide. Cancer cells are particularly impacted by reagents that 
target DNA because of their characteristic rapid proliferation rates.9 While some 
complexes’ mode of action involves permanent binding to the DNA, copper complexes 
are known for their ability to cleave DNA. The ability of a compound to induce DNA 
cleavage is also known as nuclease activity. One measure that was used to assess these 
complexes’ biological activity and potential as a chemotherapeutic agent was nuclease 
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activity.  In particular, the biological assays were used to analyze how the differing 
structures impact the overall biological activity. 
 
In order to test the complexes’ ability to cleave DNA the complexes were 
incubated with plasmid DNA in the presence of ascorbic acid. Complex concentrations 
ranged from 100 to 300 µM and were increased in 25 µM increments. A blank was also 
run without any complex present. Once the samples were incubated with the complex 
agarose gel-electrophoresis was used to separate the DNA based on size. Plasmid DNA 
can exist in several different conformations: super-coiled (SC), single-nicked (SN), and 
double-nicked (DN). Each of these conformations travels through the gel matrix at 
different rates and can therefore be distinguished from each other. This is important for 
these studies because each form of the DNA represents a different extent of cleavage; 
SC-DNA represents DNA that has not been cleaved by the complex, SN-DNA represents 
DNA that has been cut by the complex once, and DN-DNA represents DNA that has been 
cut by the complex twice. The cleavage studies, as outlined above, were carried out using 
complexes 1 and 2. Figure 6 shows representative gels from these cleavage studies.  
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Figure 6. Pictures of gels from DNA cleavage studies Complex 1 (top) complex 2 
(bottom). Reactions carried out at the concentrations of complex indicated below each gel 
in the presence of twice the concentration of ascorbic acid. Samples were incubated for 2 
h at 37°C.  
 
 
The gels showed that SN and DN-DNA were present in lanes that corresponded to 
samples incubated with complex. This indicated that the complexes are able to cleave 
DNA. Next, concentration dependent cleavage was determined. Band density analysis 
was used to determine the relative percentages of DNA in each lane on the gel. Since 
each lane corresponded to a given concentration of complex, complex concentration was 
correlated with percentages of DNA in each form. Bar graphs that show the percentages 
of DNA in each form at every concentration of complex 1 and 2 tested are depicted in 
Figure 7.  
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Figure 7. Relative percentages of DNA forms for concentration dependent cleavage 
studies. Complex 1 (top) complex 2 (bottom).  
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The percentages of DNA in the SN and DN forms are indicative of the percentage 
of DNA that was cleaved by the complex. The graphs show that even at the lowest 
concentrations of complex 1 and 2 all of the DNA has at least been converted into the SN 
form. This indicates that the complex cleaved all of the DNA at least once. The 
percentage of DNA in the DN form is equivalent to the percentage of DNA that was 
cleaved by the complex twice. The graph also shows that as the concentration of complex 
increased the percentage of DN-DNA formed also increased. This trend indicates that 
both complex 1 and 2 cleave DNA in a concentration-dependent manner, because the 
amount of cleavage is directly related to the concentration of complex. Comparison of the 
two graphs shows that more DN-DNA was formed in the presence of complex 2 than in 
the presence of complex 1 at the same concentration. This indicates that complex 2 acts 
as more efficient nuclease than complex 1. When comparing the structures of these two 
complexes the differences in reactivity can potentially be attributed to the positive charge 
on complex 2. The DNA backbone is negatively charged so the electrostatic interaction 
between the DNA and the positively charged complex (2) may be stronger than the 
interaction between DNA and neutral compound (1).  
 
3.3 DNA Cleavage Mechanistic Studies 
 
 Since it was determined that the complexes were able to cleave DNA, it was of 
interest to determine the mechanism of this cleavage. Copper complexes are known to 
cleave DNA via either a hydrolytic or oxidative mechanism.23,24 The oxidative 
mechanism requires the production of radical oxygen species (ROS).25 Common ROS 
that have been implicated in this type of cleavage include singlet oxygen (1O2), hydroxyl 
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radical (OH), and super oxide.25,26  The hydrolytic mechanism requires water to induce 
nucleophilic attack of the DNA phosphate backbone.24 Initial cleavage studies showed 
that in the presence of water but the absence of a reductant (ascorbic acid) needed to 
induce a Cu(II)/Cu(I) redox couple that generates ROS2, the complexes did not exhibit 
cleavage. This indicates that a hydrolytic mechanism is not invoked in the DNA cleavage 
exhibited by complexes 1 and 2. In order to ascertain if an oxidative mechanism was 
followed, DNA cleavage reactions were carried out with the addition of known radical 
oxygen scavengers. These scavengers remove all the ROS of a particular type from 
solution. The underlying motivation for conducting these studies is that if the removal of 
a particular ROS impacts reactivity, then that implicates that ROS in the mechanism as 
well as confirms that an oxidative mechanism is followed. 
 
Studies were carried out using L-histidine, which is a known singlet oxygen (1O2) 
scavenger.27 These reaction were carried out by incubating the DNA with varying 
concentration of complex in the presence of a constant concentration of L-histidine (Fig. 
8). The gels show that single nicked DNA was formed but DN-DNA was not. This 
contrasts with the results of the initial cleavage studies carried out in the absence of 
scavenger, which did show the production of DN-DNA. Figure 9 shows bar graph 
representations of the relative amounts of SC and SN-DNA at each concentration of 
complex 1 and 2. The graphs show quantitatively that DN-DNA was not formed and the 
percentage of SN-DNA was decreased when compared with initial cleavage studies. The 
observed decrease in DNA cleavage in the presence of L-histidine indicates that 1O2 plays 
a mechanistic role in the cleavage of DNA by complex 1 and 2. The fact that SN-DNA 
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was still formed but in lower quantities indicated that the 1O2 species may play a more 
minor role in the conversion of SC-DNA to SN-DNA. The complete inhibition of the 
formation of DN-DNA indicated that 1O2 plays a major role in the conversion of SN-
DNA to DN-DNA.  
 
 
Figure 8. Pictures of gels from DNA cleavage mechanistic studies using L-histidine. 
Complex 1 (top) complex 2 (bottom). Reactions carried out at the concentrations of 
complex indicated in the presence of twice the concentration of ascorbic acid and a 
constant L-histidine concentration of 2 mM. Samples were incubated for 2 h at 37°C.  
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Figure 9. Relative percentages of DNA forms for L-histidine mechanistic studies. 
Complex 1 (top) complex 2 (bottom) (note: this plot is an average of two runs).  
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Additional mechanistic studies were conducted using DMSO, which is a known 
hydroxyl radical scavenger.26 Representative gels of these studies are shown in Figure 10. 
These gels look very similar to the gels produced from the cleavage studies without any 
inhibitor, in that SN and DN-DNA forms are seen in every lane that corresponds to 
complex. The graphical representations, shown in Figure 11, indicated that there was no 
observable reactivity difference when DMSO was added into the reaction mixture. This 
indicates that OH species do not play a role in the DNA cleavage mechanism for either 
complex 1 or 2.  
 
 
Figure 10. Pictures of gels from DNA cleavage mechanistic studies using DMSO. 
Complex 1 (top) complex 2 (bottom). Reactions carried out at the concentrations of 
complex indicated in the presence of twice the concentration of ascorbic acid and a 
constant DMSO concentration of 10% by volume. Samples were incubated for 2 h at 
37°C.  
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Figure 11. Relative percentages of DNA forms for DMSO mechanistic studies. Complex 
1 (top) complex 2 (bottom).  
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The role of ROS in the mechanism indicated that both complexes react via an 
oxidative mechanism Based on the mechanistic studies it was concluded that 1O2 plays an 
important mechanistic role in the cleavage of DNA by complexes 1 and 2, but that OH 
does not play a role in either complex’s mechanism of action. Since neither scavenger 
was able to completely inhibit nuclease activity, additional mechanistic studies need to be 
carried out to determine if other ROS, such as superoxide, are involved in the mechanism.  
 
3.4 DNA Binding Studies  
 
The exhibited nuclease activity of complexes 1 and 2 indicate that they interact 
with DNA. However, it is unclear what type of interaction(s) is (are) occurring. One of 
the goals of this project was to carry out DNA binding studies using ethidium bromide 
(EtBr) in order to determine if the complexes intercalate DNA. Compounds that exhibit 
DNA intercalation are able to insert themselves between the DNA bases. EtBr is a known 
DNA intercalating agent with a very strong binding affinity, with Kds-DNA=130E104 M-1 
(the binding constant to double-stranded DNA).28 One of the main reasons EtBr can be 
used in these types of studies is because the EtBr-DNA complex has a characteristic 
fluorescence.29,30 In the presence of a reagent that can competitively intercalate into DNA 
a decrease in this fluorescence is observed because some of the EtBr is displaced from 
the DNA where bulk solvent quenches the florescence signal.30,31 If a decrease in 
fluorescence is observed in the presence of complex within a solution containing EtBr 
and DNA then it can be concluded that the complex is an intercalating agent. 
Additionally, the amount of fluorescence quenching can be mathematically related to the 
complex’s DNA binding constant (Kbind). 
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Solutions containing a constant concentration of EtBr and CT-DNA were 
prepared with a complex concentration range of 0-105 µM. However, both complex 1 
and 2 formed a cloudy precipitate when added into the solution mixture. Since 
fluorescence data can only be collected with a clear solution, these studies are still 
inconclusive. Some preliminary work has been conducted which indicates that increasing 
the overall percentage of DMF in these solutions may prevent the formation of precipitate. 
Initial measurements using complex 2 with solution containing 30% DMF using an 
incubation time of 30 min did not show any discernable trend. Further studies are needed 
to determine if increasing the incubation time would yield different results, because the 
initial incubation time used may not have been sufficient for complete binding to occur. 
 
3.5 Protein Binding Studies  
 
Another important aspect to consider when designing chemotherapeutic agents is 
their ability to be transported throughout the body because they must reach the site of 
cancer in order to be effective. Human Serum Albumin (HSA) is the most abundant 
protein in human blood serum.32 Therefore, binding of potential chemotherapeutic agents 
to this protein is of interest when trying to determine if a compound has the potential to 
be circulated throughout the body. Additionally, some studies have found that serum 
proteins accumulate in tumor tissue so binding these proteins may help the complex 
aggregate in the desired target region.33 Bovine serum albumin is an analog to HSA that 
is found in bovine.34 Compounds’ binding constants to BSA have also been related to 
their distribution throughout, and excretion from, the body.35 BSA has a characteristic 
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fluorescence when it is free in solution and this fluorescence decreases when it is bound 
to something that decreases the exposure of its tryptophan residues.32 Similarly to the 
EtBr studies previously described, the amount of fluorescence quenching can be 
measured and used to determine a binding constant. In order to extract the binding 
constant of complex 1, solutions were prepared with varying concentration of complex in 
the presence of a constant concentration of BSA and fluorescence measurements were 
taken. The fluorescence measurements showed that complex 1 is capable of fluorescing 
in the observed region in the absence of BSA. Figure 12 shows the fluorescence of 
complex 1 in buffer with 30% DMF at concentrations from 0-110 µM with an excitation 
wavelength 280 nm over a range of 290-450 nm. The inherent fluorescence of the 
complex interfered with attempts to measure a change in the fluorescence of BSA at these 
wavelengths. Further studies should be carried out to determine if a different excitation 
wavelength can be used and to determine if complex 2 exhibits the same fluorescence.      
 
 
Figure 12. Emission spectra of complex 1 in buffer with 30% DMF. 
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3.6 Conclusions  
 
The complexes Cu(PyOMe(oBt))Cl2 (1), [Cu(PyOMe(oBt)2(NO3)]NO3 (2), and 
[Cu2(PyOMe(en))(PyOMe(enH2)2](NO3)4 (3) were successfully synthesized and 
characterized. The observed structural differences between complex 1 and 2 were a result 
of varying the starting metal. Complex 3 demonstrated an interesting ability to self-
hydrolyze, however it is still uncertain if the extent of this hydrolysis of the ligand 
backbone is consistent in each synthetic reaction. It has been demonstrated that 
complexes 1 and 2 exhibit concentration dependent nuclease activity. Additionally, 2 was 
able to act as a more efficient nuclease compared to complex 1. The differences in 
reactivity can likely be attributed to the complexes differing overall charges. Complex 2 
has an overall positive charge, whereas complex 1 is neutral. Mechanistic studies showed 
that both complex 1 and 2 cleave DNA via an oxidative mechanism and 1O2 plays a key 
role in this mechanism. Additionally, these studies showed that OH does not play a role 
in DNA cleavage by these complexes. There are several additional studies that are needed 
in order to fully characterize the biological activity of these complexes and make 
subsequent comparisons. These studies include additional mechanistic studies of other 
ROS, DNA intercalation studies using EtBr, and BSA binding studies. 
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Appendix 
 
Appendix 1. 1H NMR spectrum of PyOMe(oBt) in CDCl3. 
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Appendix 2. 1H NMR spectrum of PyOMe(en) in CDCl3. 
 
[ppm] 8  6  4  2  0 
[re
l]
 0
 
 5
 
 1
0 
 1
5 
"1-48-1 1st collection"  1  1  C:\Bruker\TopSpin3.0\examdata\tyler\chelsea
 44 
 
Appendix 3. IR spectrum of PyOMe(oBt) ligand. 
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Appendix 4. IR spectrum of Cu(PyOMe(oBt))Cl2. 
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Appendix 5. IR spectrum of [Cu(PyOMe(oBt)2(NO3)]NO3.  
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Appendix 6. IR spectrum of PyOMe(en). 
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Appendix 7. IR spectrum of [Cu2(PyOMe(en))(PyOMe(enH2)2](NO3)4.  
 
 
